Centene Eyes 2026 Earnings Rebound After Difficult 2025
Centene ((CNC)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Centene Balances Tough 2025 With Clear Path to 2026 Earnings Rebound
The tone of Centene’s latest earnings call was cautiously optimistic: management was frank about a difficult 2025 marked by marketplace pressure, regulatory noise, and persistent medical cost headwinds, yet emphasized tangible operational progress and a credible plan for a sharp earnings rebound in 2026. With Medicaid margins improving, Medicare performing strongly, SG&A efficiencies taking hold, and new data and AI tools rolling out, leadership framed 2026 as an inflection year toward margin recovery, even as they acknowledged execution risks tied to policy changes, membership attrition, and volatile clinical trends.
2026 EPS Outlook: Aiming for Meaningful Margin Recovery
Centene set a clear financial marker for investors by guiding to more than $3 in adjusted diluted EPS for 2026, a greater than 40% increase from the 2025 adjusted EPS of $2.08. This step-up is designed to be driven primarily by improved margins rather than outsized membership growth. Management presented this target as evidence that the company’s turnaround efforts—tightening medical costs, optimizing product mix, and controlling overhead—are gaining traction. The guidance implies a meaningful recovery in profitability from a challenging 2025, laying the groundwork for longer-term earnings momentum beyond 2026.
Medicaid HBR Improvement Signals Stabilizing Core Business
A bright spot in the call was Medicaid, where Centene’s health benefits ratio (HBR)—a key measure of medical cost efficiency—showed consistent improvement. The Medicaid HBR in Q4 came in at 93, a 40-basis-point sequential improvement and nearly 190 basis points better than Q2 2025. For 2026, management is targeting HBR stability supported by net rate increases in the mid-4% range (around 4.5%), closely aligned with expected medical cost trend. This suggests the company is regaining balance with state partners and better matching rates to underlying risk, even as volumes and acuity shift after the large eligibility redeterminations seen across the sector.
Medicare and PDP: Growth Engine With Balanced Profit Expectations
Centene’s Medicare business emerged as a key growth driver, offsetting weakness in other lines. The Medicare segment delivered strong 2025 results, and management expects premium revenue to grow by about $7.5 billion in 2026, with Part D enrollment tracking to high single-digit percentage growth. The revenue mix is expected to skew roughly 41% Medicare Advantage (MA) and 59% Prescription Drug Plans (PDP). While PDP pretax margins are projected to normalize down to about 2% in 2026 from the high‑3% range in 2025, management emphasized that MA remains on track toward breakeven by 2027. The message to investors: Medicare remains a strategic growth platform, but Centene is prioritizing sustainable profitability over chasing volume at any cost.
Consolidated HBR and Cost Discipline Underscore Operating Leverage
On a consolidated basis, Centene guided to a health benefits ratio of 90.9%–91.7% for 2026, with the midpoint representing roughly a 60-basis-point improvement versus 2025, signaling gradual but meaningful progress in controlling medical costs. At the same time, the company has been tightening its cost structure, with full-year adjusted SG&A at 7.4%, an improvement of 110 basis points versus 2024. Management highlighted this as evidence of operating leverage: as revenue scales and automation increases, administrative costs should consume a smaller share of the top line. For investors, the combination of a lower HBR and a leaner SG&A profile supports the case for improved earnings resilience.
Balance Sheet and Liquidity: Deleveraging to Strengthen the Foundation
Centene also leaned into balance sheet discipline, ending the year with about $400 million of cash available for general corporate purposes and reducing debt by $189 million in the fourth quarter. The company closed the year with a debt-to-capital ratio of 46.5%, signaling ongoing deleveraging efforts. While still elevated, the trend reflects a deliberate move to improve financial flexibility, reduce interest expense over time, and maintain the capacity to invest in core operations. Management’s emphasis on balance sheet health will likely be welcomed by investors wary of macro volatility, interest rate uncertainty, and policy risk in government-sponsored healthcare.
Operational and Data/AI Advances to Drive Efficiency
Management spotlighted the build-out of data and AI capabilities as a key lever for future margin improvement. Centene is deploying AI to accelerate prior authorization reviews, streamline call center operations, and enhance payment integrity, including scoring claims against a library of 75 algorithms to better catch errors and inappropriate billing. These tools are intended to both improve member and provider experience and help curb medical and administrative costs. While the financial impact will be phased in over time, the company portrayed these digital initiatives as central to its ability to manage complex medical trends and improve care management at scale.
2025 Earnings and Q4 Adjusted Loss Reflect a Tough Transition Year
The company did not sugarcoat 2025 performance. Centene reported a Q4 adjusted diluted loss per share of $1.19 and full-year adjusted EPS of $2.08, underscoring a year weighed down by marketplace pressures, elevated medical costs, and one-time items. Q4 GAAP diluted loss per share was $2.24, driven in part by a $389 million net loss tied to a definitive agreement to divest the remaining Magellan business. Management framed 2025 as a transition year: painful in the near term but necessary to clean up the portfolio, reset pricing, and reposition for a more sustainable earnings path starting in 2026.
Marketplace Membership and Revenue Hit by Policy Shifts
Centene’s Ambetter marketplace business has been heavily impacted by policy and market changes, especially the shift in advance premium tax credits and the post‑EAPTC environment. Paid marketplace membership fell from roughly 5 million in December to an expected 3.5 million by the end of Q1 2026. As a result, the company expects marketplace revenue to be down about $8 billion in 2026. Management highlighted that product mix is shifting, with bronze plans rising to over 30% of membership, and that pricing has been adjusted to reflect the new regulatory and competitive realities. The segment’s sharp revenue decline is a major headwind, but Centene expects margins in marketplace to recover as pricing and mix reset.
No Surprises Act Volatility Adds to Marketplace Headwinds
The No Surprises Act (NSA) was another pressure point, particularly in the marketplace business. Centene recorded two out‑of‑period items in Q4—a 2023 Centers for Medicare & Medicaid Services reconciliation and higher NSA dispute-related costs—that together pushed the marketplace HBR up by about 100 basis points versus prior expectations. Management warned that NSA-related disputes and reconciliations could continue to add volatility going forward. The company is pursuing litigation and policy advocacy to help address the current arbitration and reimbursement framework, but in the meantime investors should expect some noise in quarterly results stemming from this regulatory environment.
Persistent Clinical Cost Drivers Challenge Medical Trend
Centene continues to battle elevated medical cost trends in key areas, especially behavioral health, home health, and high-cost specialty drugs. Behavioral health alone accounted for roughly half of the excess medical trend in 2025, illustrating how post‑pandemic utilization patterns and acuity are reshaping cost structures. The company is responding with more aggressive care management programs, tighter network strategies, and more active rate discussions with state partners. Nonetheless, management acknowledged these clinical cost drivers will remain a core challenge and a key swing factor in how quickly margins can normalize.
Medicaid Membership Attrition Remains a Drag
Despite improving margins, Centene’s Medicaid membership base is shrinking as states continue eligibility reverifications and certain programs roll off. The company expects Medicaid member months to decline about 5%–6% in 2026, implying year‑end membership around 12.5 million. This attrition, coupled with shifts in acuity as healthier members leave and more complex patients remain, is a structural headwind. Management stressed that while rates and programs are being recalibrated to reflect these changes, the volume decline tempers the speed of overall margin recovery in the Medicaid book.
Seasonality and Earnings Profile Point to 2026 Volatility
Centene’s 2026 earnings profile will be highly seasonal, with management guiding to a front‑loaded year: the majority of adjusted EPS is expected in the first quarter, stepping down in the second quarter, roughly breakeven in the third, and a loss in the fourth. This pattern reflects the timing of premium recognition, risk adjustment, and utilization patterns, as well as the evolution of marketplace and Medicare dynamics through the year. For investors, the implication is that quarterly volatility should be expected, and that the full‑year picture is more important than any single quarter’s performance.
Guidance and Outlook: Growth, Margin Recovery, and Execution Risk
Centene’s 2026 guidance calls for premium and service revenue of $170–$174 billion, a consolidated HBR of 90.9%–91.7%, and adjusted EPS above $3, representing more than 40% growth versus 2025. Medicaid is expected to maintain a stable HBR with net rate and trend in the mid‑4% range despite a 5%–6% decline in member months. Marketplace revenue is projected to fall by about $8 billion, but pretax margins are expected to recover to roughly 4% from a loss in 2025 as pricing and product mix reset. Medicare is slated to add about $7.5 billion in premium revenue, with PDP margins normalizing near 2% and Medicare Advantage still progressing toward breakeven in 2027. The company also expects an adjusted SG&A ratio around 7.4%, a medical claims liability of roughly $20.5 billion (about 46 days), and no share buybacks embedded in guidance. Overall, the outlook positions 2026 as a rebuilding year with significant margin expansion, though one still exposed to regulatory and clinical cost volatility.
In sum, Centene’s earnings call painted a picture of a company working through a difficult reset while laying the groundwork for a stronger 2026. Management acknowledged real headwinds—shrinking marketplace revenue, Medicaid attrition, NSA noise, and stubborn behavioral health and drug costs—yet highlighted concrete progress in Medicaid margins, Medicare growth, SG&A efficiency, balance sheet strength, and digital capabilities. For investors, the story is one of near‑term volatility and execution risk, but with a credible path toward improved margins and earnings growth as the company moves into 2026 and beyond.
